H.C. Wainwright analyst Andrew Fein notes that Arvinas (ARVN) shared the final data from the VERITAC-2 trial, which the firm sees positioning vepdegestrant as the first-ever oral PROTAC potentially approved for ESR1-mutant patients. The firm thinks that the trial data likely unlocks a milestone payment, but beyond regulatory success, the Pfizer (PFE) partnership dynamics may shift given that Arvinas management has suggested that co-commercialization may be less appealing for both companies given the relatively small target patient population, the analyst tells investors. The structure of this partnership “might be critical in shaping Arvinas’ strategies going forward” as negotiations unfold in the coming weeks, adds the analyst, who has a Buy rating and $24 price target on Arvinas shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Buy Rating Justified by Arvinas Holding’s Promising Early-Stage Pipeline Despite Modest Trial Results
- Arvinas and Pfizer Announce Phase 3 Trial Results
- Hold Rating on Arvinas Holding Amid Uncertainties in Vepdegestrant’s Market Potential
- Arvinas downgraded to Market Perform from Outperform at Leerink
- Arvinas, Pfizer announce VERITAC-2 trial did not reach statistical significance